Discomfort and localtoxicity often cause interruption of intravesical adjuvant therapy for nonmuscle invasive bladder cancer (NMIBC). A marker of urothelial damagecould be helpful for early detection and monitoring of topical toxicityto ameliorate the tolerability of the intrravesical therapy. The aim of thestudy is to investigate the correlation between the gene expression ofFibronectin (FN) in bladder washings and local toxicity of adjuvantintravesical therapy.
|Number of pages||1|
|Publication status||Published - 2015|